Memory and sleep disorders in an outpatient setting
Abstract
The paper describes cases that clearly demonstrate that the neurological status shows a preponderance of cognitive, emotional, and behavioral disorders in both cerebral vascular and neurodegenerative diseases just at the early stages. At the same time sleep disorders occupy the most important place among the behavioral disorders. So a neurologist must have advanced knowledge of this problem and practical skills in diagnosing neuropsychological disorders. Only consideration of all their clinical features allows the use of effective treatment that is able to improve the quality of life in a patient and his relatives, to prevent or delay the occurrence of severe complications.
References
1. <div><p>Михайлова Н.М. Нарушения сна в пожилом и старческом возрасте. Клинические рекомендации по лечению. РМЖ 2003;28:1610-3.</p><p>Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол журн 2006;11:27-32.</p><p>DiCarlo A., Baldereschi M., Amaducci L. еt al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. Italian Longitudinal Study on Aging. J Am Ger Soc 2000;48:775-82.</p><p>Graham J.E., Rockwood K., Beattie E.L. et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-6.</p><p>Захаров В.В. Применение танакана в нейрогериатрической практике. Неврол журн 1997;5:42-9.</p><p>Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Танакан (Egb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн неврол и психиатр 2006;106(12):41—6.</p><p>Andrieux S., Amouyal K., Renish W. et al. The consumption of vasodilators and Ginkgo biloba (Egb 761) in a population of 7598 women over the age of 75 years. Res pract Alzheim dis 2001;5:57-68.</p><p>Lemoine P., Nir T., Laudon M., Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80.</p><p>Wade A.G., Ford I., Crawford G. et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23(10):2597—605.</p><p>Wade A.G., Ford I., Crawford G. et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:51.</p><p>Luthringer R., Muzet M., Zisapel N., Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24(5):239-49.</p></div><br />
Review
For citations:
Zakharov V.V. Memory and sleep disorders in an outpatient setting. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(1):54-58. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2400
Views: 688
Email this article 